WixBio recently supplied 2,000 bottles of 500ml quadrivalent inactivated vaccine for Newcastle Disease (ND), Infectious Bronchitis (IB), Avian Influenza (H9), and Fowl Adenovirus (FADV) to a Turkish client. This product was custom-developed to meet the client’s specific requirements and align with the characteristics of local epidemic strains, showcasing WixBio’s expertise in vaccine research, precise strain matching, and efficient delivery.
The quadrivalent inactivated vaccine incorporates key antigenic components targeting prevalent poultry diseases in the region. Vaccine seeds were selected to match current epidemic strains, ensuring robust immune protection and broad cross-protection. Developed and manufactured under strict Good Manufacturing Practice (GMP) standards, the vaccine underwent rigorous multi-stage quality control to guarantee batch consistency, high potency, and safety.
To meet the client’s stringent requirements for product quality, packaging, and delivery timelines, WixBio streamlined operations across production scheduling, quality release, and cold-chain logistics. A fully temperature-controlled transport system maintained the vaccine at a temperature range of 2–8°C throughout the supply chain, preserving its biological activity.
Client feedback highlighted: “This tailored vaccine closely aligns with local epidemic strains and demonstrates exceptional performance in immune efficacy, antibody persistence, and safety, significantly improving the economic outcomes for our end users.”
This collaboration underscores WixBio’s commitment to a “customer-centric, science-driven” approach. The company remains dedicated to expanding its global presence, leveraging advanced customized R&D capabilities and a robust international supply chain to deliver precise, reliable, and efficient animal health solutions to partners worldwide.
